Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2560)	8/13/2009 11:56:49 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

BPAX is still up 26.41% on volume of 3.1M, about 30x its ADV.<g> The stock opened with a good UG and it traded for a while above its Jun4 H of $2.67 bigcharts.marketwatch.com It announced positive safety data in its ongoing LibiGel PIII.<g> It reported that with over 1,250 women enrolled and almost 825 women-years of exposure in its PIII,there have been no deaths and only five cardiovascular events. BPAX is planning submission to the FDA of an NDA by mid-2011. The LibiGel safety study is tracking a predefined list of cardiovascular events, in agreement with the FDA, including cardiovascular death, myocardial infarction and stroke, in women 50 years of age or older and suffering from at least two cardiovascular risk factors including hypertension and diabetes. BPAX is also conducting two LibiGel PIII efficacy trials that will enroll up to approximately 500 surgically menopausal women each for a six-month clinical trial. The efficacy trials are being conducted under an FDA approved SPA. In a PII the drug significantly increased satisfying sexual events in surgically menopausal women suffering from FSD.In that study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. On June 30 BPAX also announced that it was taking over CEGE in a $38M stock deal.Although the combined firm was going to focus primarily on LibiGel, with the additional cash from CEGE (As of June 23, CEGE’ cash balance was approximately $36M while BPAX's was roughly $6.2M.<g>)It will also evaluate development opportunities for GVAX, including potential combination with BioVant. In spite of its negative CF, since BPAX has negligible LTD and has now the extra cash infusion from CEGE, it seems that it could be able to test the resistance at the $4 and even the $6 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2560)	8/28/2009 1:08:11 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

After making an all time H on Aug14, TPI has been on a near term DT, but it is trying to find support at $3.30, with a more important looking one at $3.10 <g> bigcharts.marketwatch.com The stock remains on its medium term UT that started in March from the $1 level. bigcharts.marketwatch.com On June 18 it said that it expects that its revenues for the current Yr. will be up 25% to $42M and income up 26% to $7.5M, although the official results and CC aren't due until next month.<g> For 2010 the estimates for net income are around $0.55/shr On YHOO the 'forward PE' is around 6.28 vs. 11.81 at present.<g> finance.yahoo.com I think I will keep my 'target' for TPI at $5 <g> bigcharts.marketwatch.com Disclosure: I have been trading the stock in order to keep my cost down, but am still long and planning on buying more.<g> Bernard